EBS

EMERGENT BIOSOLUTIONS INC COM

EBS·29089Q105·US·Common Stock·Healthcare - Drug Manufacturers - Specialty & Generic-13D/G

EBS (EMERGENT BIOSOLUTIONS INC COM) is held by 105 institutional investors as of Q2 2026. Largest holders: BlackRock, Inc. ($39.5M), DIMENSIONAL FUND ADVISORS LP ($25.8M), STATE STREET CORP ($24.6M). Net institutional sentiment: Mixed.

105
Holders
(11 Elite)
$297.2M
Total Value
56% (103)
Consensus
58 buying - 45 selling
13F: Insider & Congress: Updated regularly
EBS

Smart Money Verdict

View all
Loading verdict
Held by 105 funds
11 elite

Who's Trading

Source dates: Price Oct 9, 2026 · Insiders Oct 7, 2026 · Activists Aug 14, 2026 · Congress Jan 10, 2025

InsiderDWDeGolyer Donald WSell $126KOct 7, 2026
InsiderWAWilliams Paul AnthonySell $20KOct 1, 2026
ActivistACAmerican Century Investment Management, Inc.5.4%Aug 14, 2026
Checking access…

Top Holders

Checking access…
Action
Increased
4.7M(+8.6%)$39.5M0.0%-11.10%
32
Increased
3.1M(+11.6%)$25.8M0.0%-15.33%
32
Increased
2.9M(+2.8%)$24.6M0.0%-15.44%
29
Increased
2.8M(+14.2%)$23.2M0.0%-20.05%
33
Decreased
2.2M(-2.6%)$18.4M0.0%-23.65%
0
Increased
1.3M(+5.0%)$11.2M0.0%-70.87%
29
Decreased
1.2M(-20.3%)$10.1M0.0%-27.85%
0
Increased
1.1M(+101.5%)$9M0.0%-23.70%
44
Increased
1M(+5.2%)$8.7M0.0%-23.50%
29
Increased
1M(+27.6%)$8.7M0.0%-24.96%
34
Decreased
1M(-7.9%)$8.6M0.0%-23.65%
0
Decreased
900,108(-10.3%)$7.5M0.0%-40.84%
0
Increased
859,482(+155.9%)$7.2M0.0%-17.06%
44
Increased
831,125(+82.1%)$7M0.0%-18.62%
42
Increased
805,895(+79.6%)$6.8M0.0%-21.57%
42
Increased
683,247(+4.2%)$5.7M0.0%-5.42%
28
Increased
621,473(+3.4%)$5.2M0.0%-55.02%
28
Increased
543,781(+15.8%)$4.6M0.0%-18.80%
31
Unchanged
513,904$4.3M0.0%-64.77%
0
Decreased
488,284(-15.4%)$4.1M0.0%-19.27%
0

Showing 1-20 of 112

1 / 6
EBSEBSEMERGENT BIOSOLUTIONS INC COM

Other Healthcare stocks held by institutions

Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used